Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells

Tools
- Tools
+ Tools

UNSPECIFIED (2005) Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. BRITISH JOURNAL OF PHARMACOLOGY, 145 (1). pp. 114-122. ISSN 0007-1188

Full text not available from this repository.

Abstract

1 Asthma is an inflammatory disease of the lungs and the transcription factor NF-κ B regulates the production of numerous inflammatory mediators that may have a role in the pathogenesis of asthma. Hence, the signalling pathways leading to NF-κ B activation are considered prime targets for novel anti-inflammatory therapies. The prevention of NF-κ B activity in mice, through the knockout of IKKβ or p65, causes fatal liver degeneration in utero making it difficult to determine the full implications of inhibiting NF-κ B activity in tissues physiologically relevant to human diseases. 2 This study used adenovirus delivery of a dominant inhibitor of NF-κ B(Iκ Bα&UDelta; N) and dominant-negative IKKα (IKKα(KM)) and IKKβ (IKKβ(KA)) to investigate the role of the individual IKKs in NF-κ B activation and inflammatory gene transcription by human pulmonary A549 cells. 3 Overexpression of IKKβ(KA) or IkBα&UDelta; N prevented NF-κ B-dependent transcription and DNA binding. IKKβ(KA) also prevented Iκ Bα kinase activity. Similarly, IKKβ(KA) and Iκ Bα&UDelta; N overexpression also inhibited IL-1β- and TNFα-dependent increases in ICAM-1, IL-8 and GMCSF in addition to IL-1β- mediated increases in cyclooxygenase-2 expression, whereas IKKα(KM) overexpression had little effect on these outputs. 4 IKKβ(KA) also reduced cell viability and induced caspase-3 and PARP cleavage regardless of the stimuli, indicating the induction of apoptosis. This effect seemed to be directly related to IKKβ kinase activity since Iκ Bα&UDelta; N only induced PARP cleavage in TNFα-treated cells. 5 These results demonstrate that inhibition of IKKβ and NF-κ B suppresses inflammatory mediator production and reduces A549 cell viability. Thus, novel therapies that target IKKβ could have potent anti-inflammatory effects and may be beneficial in the treatment of certain cancers.

Item Type: Journal Article
Subjects: R Medicine > RS Pharmacy and materia medica
Journal or Publication Title: BRITISH JOURNAL OF PHARMACOLOGY
Publisher: NATURE PUBLISHING GROUP
ISSN: 0007-1188
Date: May 2005
Volume: 145
Number: 1
Number of Pages: 9
Page Range: pp. 114-122
Publication Status: Published
URI: http://wrap.warwick.ac.uk/id/eprint/7067

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us